Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers VCYT said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $582.00M to $592.00M release May 5, 2026
Raised $590.00M to $596.00M release Jul 30, 2026
Lowered $590.00M to $593.00M release Nov 4, 2026
– Not reported yet
The company's words
The company is raising 2026 total revenue guidance to $582 million to $592 million, or 13% to 14% growth, from prior guidance of $570 to $582 million, or 10% to 13% growth. release May 5, 2026
The company is raising 2026 total revenue guidance to $590 million to $596 million, or 14% to 15% growth, from prior guidance of $582 to $592 million, or 13% to 14% growth. release Jul 30, 2026
Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million. release Nov 4, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $470.00M to $480.00M release Feb 24, 2025
Kept $470.00M to $480.00M release May 7, 2025
Raised $496.00M to $504.00M release Aug 6, 2025
Raised $506.00M to $510.00M release Nov 4, 2025
$517.14M
10-K filed 2026-02-26
Above the range
The company's words
The company expects 2025 testing revenue to be in the range of $470 million to $480 million, or 12% to 15% year-over-year growth. release Feb 24, 2025
The company is reiterating full-year 2025 testing revenue guidance of $470 million to $480 million, or 12% to 15% year-over-year growth. release May 7, 2025
Provided full year revenue guidance of $496 million to $504 million; raised testing revenue guidance to $477 million to $483 million or 14% to 15% year- over-year growth. release Aug 6, 2025
Raised full year revenue guidance to $506 million to $510 million, including raising testing revenue guidance to $484 million to $487 million or 16% year- over-year growth. release Nov 4, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $394.00M to $402.00M release Feb 22, 2024
Raised $402.00M to $410.00M release May 7, 2024
Raised $432.00M to $438.00M release Aug 6, 2024
Raised $442.00M to $445.00M release Nov 6, 2024
$445.76M
10-K filed 2025-02-28
Above the range
The company's words
The company is maintaining full-year 2024 total revenue guidance of $394 million to $402 million and consistent with prior guidance, expects cash, cash equivalents and short-term investments at the end of the year to be $230 million to $234 million. release Feb 22, 2024
The company is raising full-year 2024 total revenue guidance to $402 million to $410 million, representing year-over-year growth of 11% to 14% and testing growth of 15% to 18%. release May 7, 2024
The company is raising full-year 2024 total revenue guidance to $432 million to $438 million, representing year-over-year growth of 20% to 21% and testing revenue growth of approximately 25%. release Aug 6, 2024
The company is raising full-year 2024 total revenue guidance to $442 million to $445 million, representing year-over-year growth of 22% to 23% and testing revenue growth of approximately 28%. release Nov 6, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.